CureDuchenne and Catabasis Pharmaceuticals to Host a Webinar to Review Information on Edasalonexent (CAT-1004) and the MoveDMDSM Trial on June 22, 2016

NEWPORT BEACH, Calif. & CAMBRIDGE, Mass.--()--CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, and Catabasis Pharmaceuticals, Inc., (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will host a webinar “MoveDMD: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy” on Wednesday, June 22, 2016 at 1 p.m. ET/10 a.m. PT.

Speakers include:

  • Dr. Joanne Donovan, Chief Medical Officer, Catabasis
  • Debra Miller, Founder and CEO, CureDuchenne
  • Dr. Michael Kelly, Chief Scientific Advisor, CureDuchenne

Dr. Donovan will discuss the positive results from Part A of the MoveDMD trial and review the design and inclusion criteria of Part B (Phase 2) that is currently running. The MoveDMD trial is a Phase 1/2 clinical trial of edasalonexent in boys with Duchenne between the ages of 4 and 7. The goal of Part A included evaluation of the safety and tolerability of edasalonexent. Part B will evaluate the safety and efficacy of edasalonexent in boys with Duchenne.

Dr. Donovan, who received her academic training at MIT, Harvard and Brigham & Women’s Hospital, has more than 15 years of experience in drug development, taking programs from Phase 1 to approval. Dr. Donovan is currently an Associate Clinical Professor of Medicine at Harvard and continues to practice and teach medicine.

Duchenne muscular dystrophy is a rare, degenerative muscle disease that affects 1 in 3,500 boys. Boys with Duchenne are usually diagnosed by age 5, lose their ability to walk by age 12 and most don’t survive their mid-20s.

To register for the webinar on June 22, click here. The call in number is (844) 337-8088 and the conference ID number is 25189236.

About CureDuchenne

CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy. Affecting 1 in 3,500 boys, Duchenne is the most common and lethal form of muscular dystrophy. CureDuchenne has garnered international attention for its innovative model of funding the most impactful research through venture philanthropy and providing patient care through CureDuchenne Cares. For additional information, please visit and follow us on Facebook, Twitter and YouTube.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit


Karen Harley, 949-872-2552


Social Media Profiles


Karen Harley, 949-872-2552